News
XCUR
2.400
-4.76%
-0.120
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 3d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 4d ago
Weekly Report: what happened at XCUR last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at XCUR last week (0608-0612)?
Weekly Report · 06/15 09:00
Exicure Receives Nasdaq Notification For Failure To Maintain Minimum Stockholders' Equity
NASDAQ · 06/11 08:14
Exicure receives Nasdaq notice over stockholders' equity requirement
Seeking Alpha · 06/10 20:09
Exicure Receives Nasdaq Noncompliance Notice, Gets Time Through July 20 To Regain Compliance
Benzinga · 06/10 20:01
Exicure gets Nasdaq notice for falling below $2.5 million stockholders’ equity requirement
PUBT · 06/10 20:01
EXICURE ANNOUNCES RECEIPT OF NASDAQ NOTICE REGARDING MINIMUM STOCKHOLDERS’ EQUITY REQUIREMENT
Reuters · 06/10 20:01
Weekly Report: what happened at XCUR last week (0601-0605)?
Weekly Report · 06/08 09:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 06/04 21:05
Where short sellers are betting in micro- and small-cap stocks
Seeking Alpha · 06/04 13:45
Most and least shorted healthcare stocks with market cap up to $2B at the end of May
Seeking Alpha · 06/03 13:45
Exicure Receives Nasdaq Delinquency Notice; Stock Down
NASDAQ · 06/02 09:40
Exicure receives noncompliance notification from Nasdaq
TipRanks · 06/01 20:21
Exicure receives Nasdaq notice for delayed Q1 filing
Seeking Alpha · 06/01 20:08
Exicure Regains Nasdaq Compliance After Late Quarterly Filing
TipRanks · 06/01 19:58
EXICURE ANNOUNCES RECEIPT OF NASDAQ DELINQUENCY NOTICE AND FILING OF FORM 10-Q
Reuters · 06/01 19:31
EXICURE - FILES Q1 2026 10-Q ON MAY 29, 2026; BELIEVES NASDAQ COMPLIANCE REGAINED
Reuters · 06/01 19:31
Weekly Report: what happened at XCUR last week (0525-0529)?
Weekly Report · 06/01 09:00
More
Webull provides a variety of real-time XCUR stock news. You can receive the latest news about Exicure Inc through multiple platforms. This information may help you make smarter investment decisions.
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.